Internal Medicine, Infectious Disease · Joliet, IL
NPI
1306947536
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1051 Essington Rd, Suite 210
Joliet, IL, 60435
Phone (815) 726-1818
Groups this clinician bills Medicare through
Medicare paid, 2024
$89K
3,049 services
Medicare patients, 2024
229
Average age 76
Drug cost, 2024
$1.1M
939 prescriptions
Company payments, 2025
$327
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dan Anthony C Garganera was code 99233 (hospital e&m - subsequent), 278 times for 130 patients. In total Dan Anthony C Garganera billed 3,049 services in 14 codes, and Medicare paid $89K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-02-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 278 | 130 | $94.29 | $26K |
| 99232 Hospital E&M - Subsequent | Facility | 181 | 110 | $60.35 | $11K |
| 99223 Hospital E&M - Initial | Facility | 99 | 97 | $134.12 | $13K |
| 99214 Office E&M - Established | Office | 29 | 23 | $69.55 | $2,017 |
By year: 2022 $208K for 2,441 services; 2023 $221K for 6,276 services; 2024 $89K for 3,049 services.
Medicare prescription drug claims, 2024
In 2024, the drug Dan Anthony C Garganera prescribed most often to Medicare patients was Descovy (Emtricitabine/Tenofov Alafenam), with 59 prescriptions and refills. In total Dan Anthony C Garganera wrote 939 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Descovy Emtricitabine/Tenofov Alafenam | 59 | 59 | Under 11 | $133K |
| Tivicay Dolutegravir Sodium | 52 | 52 | Under 11 | $126K |
| Cabenuva Cabotegravir/Rilpivirine | 37 | 57 | 11 | $260K |
| Prezcobix Darunavir/Cobicistat | 33 | 33 | Under 11 | $81K |
| Testosterone Cypionate Generic | 32 | 32 | Under 11 | $569 |
| Dovato Dolutegravir Sodium/Lamivudine | 28 | 28 | Under 11 | $83K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 28 | 28 | Under 11 | $117K |
| Azithromycin Generic | 25 | 25 | Under 11 | $645 |
| Doxycycline Monohydrate Generic | 25 | 31 | 14 | $699 |
| Cefdinir Generic | 22 | 22 | 19 | $232 |
| Abrysvo Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 | 21 | $6,673 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 21 | 21 | Under 11 | $84K |
| Meropenem Generic | 21 | 21 | Under 11 | $2,291 |
| Valacyclovir Valacyclovir Hcl | 20 | 28 | Under 11 | $1,061 |
| Juluca Dolutegravir/Rilpivirine | 19 | 19 | Under 11 | $65K |
Brand drugs: 443 claims; generic drugs: 496 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dan Anthony C Garganera $327 ($327 in general payments such as food, travel and fees) from 5 companies. The largest payer was ViiV Healthcare Company with $186.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.